CFR Chemaphor Inc.

Chemaphor Inc. (TSX VENTURE: CFR), today announced that it has issued a total of 1,560,000 common shares and 780,000 common share purchase warrants for gross proceeds of $156,000 through a private placement. This closing represents the first closing with at least one additional closing expected to occur this month on the same terms. Any future closings will be disclosed as they occur.

This private placement involves the sale of units, each comprised of one common share and one half of a common share purchase warrant, for a unit price of $0.10. Each whole warrant entitles the holder to acquire one common share of Chemaphor at an additional purchase price of $0.10 per share for two years from closing. The warrants are subject to an accelerated expiry if, at any time after an initial 4 month hold period expires, the closing price of Chemaphor's common shares on the TSX Venture Exchange exceeds $0.20 for any 20 consecutive trading days, in which event the holder will be given notice that the warrants will expire 30 days following the date of such notice. The warrants may be exercised by the holder during the 30-day period between the notice and the expiration of the warrants.

Chemaphor used and expects to use the services of agents in connection with the placement, including Bloom Burton & Co. For such services agents will receive, in the aggregate, cash commissions equal to up to 10% of the amount raised and broker warrants entitling the agents to acquire a number of common shares equal to up to 10% of the number of units sold. The warrants to be issued to agents will have the same terms as the warrants issued to subscribers in the private placement.

The net proceeds of the proposed offering will be used to fund working capital and research and development expenditures and for general corporate purposes.

The securities issued under this private placement are and will be subject to restrictions on transfer, including a hold period ending four months after issuance. The private placement remains subject to TSX Venture Exchange approval. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering natural health optimizer ("NHO") products to humans and animals to assist in optimizing health and daily quality of life. Chemaphor is advancing NHO product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at www.chemaphor.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Chemaphor Inc. Dr. Graham Burton 613-990-0969 Investor Relations Evolution Group Inc. Sylvain Archambault President 1-866-703-4887 s.archambault@evolutiongrp.com